Free Trial

PTC Therapeutics (PTCT) Stock Price, News & Analysis

PTC Therapeutics logo
$64.48 +0.58 (+0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$64.54 +0.06 (+0.10%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PTC Therapeutics Stock (NASDAQ:PTCT)

Advanced

Key Stats

Today's Range
$63.31
$65.22
50-Day Range
$43.30
$65.37
52-Week Range
$35.51
$67.40
Volume
1.04 million shs
Average Volume
1.12 million shs
Market Capitalization
$5.12 billion
P/E Ratio
9.25
Dividend Yield
N/A
Price Target
$69.00
Consensus Rating
Moderate Buy

Company Overview

PTC Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

PTCT MarketRank™: 

PTC Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 287th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 9 buy ratings, 6 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for PTC Therapeutics is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    PTC Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about PTC Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PTC Therapeutics is 9.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 234.07.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PTC Therapeutics is 9.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.73.

  • Read more about PTC Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.18% of the outstanding shares of PTC Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 9.79%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PTC Therapeutics does not currently pay a dividend.

  • Dividend Growth

    PTC Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.18% of the outstanding shares of PTC Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 9.79%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    PTC Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for PTC Therapeutics this week, compared to 9 articles on an average week.
  • Search Interest

    6 people have searched for PTCT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,378,035.00 in company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of PTC Therapeutics is held by insiders.

  • Read more about PTC Therapeutics' insider trading history.
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PTCT Stock News Headlines

PTC Therapeutics (NASDAQ:PTCT) VP Sells $147,448.62 in Stock
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.tc pixel
PTC Therapeutics (NASDAQ:PTCT) VP Sells $1,382,504.00 in Stock
See More Headlines

PTCT Stock Analysis - Frequently Asked Questions

PTC Therapeutics' stock was trading at $45.14 at the beginning of 2025. Since then, PTCT stock has increased by 42.8% and is now trading at $64.4780.

PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings results on Thursday, August, 7th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.24. The business's revenue was down 4.2% compared to the same quarter last year.
Read the conference call transcript
.

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

Last Earnings
8/07/2025
Today
10/08/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PTCT
CIK
1070081
Employees
1,410
Year Founded
1998

Price Target and Rating

High Price Target
$118.00
Low Price Target
$42.00
Potential Upside/Downside
+7.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
$6.97
Trailing P/E Ratio
9.25
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$363.30 million
Net Margins
35.65%
Pretax Margin
37.74%
Return on Equity
-106.31%
Return on Assets
30.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.62
Quick Ratio
3.57

Sales & Book Value

Annual Sales
$806.78 million
Price / Sales
6.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($14.24) per share
Price / Book
-4.53

Miscellaneous

Outstanding Shares
79,440,000
Free Float
75,069,000
Market Cap
$5.12 billion
Optionable
Optionable
Beta
0.55

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:PTCT) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners